Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
about
FGFR3-TACC3 fusion in solid tumors: mini reviewThe potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Current status and perspectives of patient-derived xenograft models in cancer research.Emerging molecular targets and therapy for cholangiocarcinoma.Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.Promising therapeutics of gastrointestinal cancers in clinical trials.Dovitinib enhances temozolomide efficacy in glioblastoma cells.Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.CCDC6: the identity of a protein known to be partner in fusion.Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Molecular genomic landscapes of hepatobiliary cancer.RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
P2860
Q26740578-58D3DC9C-C570-4385-B8BF-35A6DDDEC6B7Q33656860-65B5272F-B44A-4193-BCA2-6D06E034A2A1Q33667686-DA679C94-6F0D-4B6E-BE1A-CFBD9440A9EEQ38642455-99E6FBEC-B61F-4254-9606-9B8DEC255064Q38776411-96ECB7BC-BAC5-4378-96A2-BB9D45518462Q39120148-5F8C6AD3-0A15-45D1-91E0-6CFF474568B2Q39453620-0C8A16E6-6B74-4732-9A26-310AE09B65CAQ40214485-F64F2B8A-35DC-4DBE-A665-D3776DA19211Q47285585-DECAB5EB-AA20-4B01-9142-4F55353C8067Q47429093-3D2CF23C-0EDC-4A93-AD03-373CBEE9A3A2Q47634740-171D4A8B-055D-40BA-8541-81693CE25B78Q48649855-4099FD09-CC36-4A63-BF5B-069EB5E22D3EQ49887888-1D3641FA-D2D4-4AAC-A359-C1F9202C3E5CQ52343716-38EA0602-FC62-4A49-9CD5-5A9DAFD96D93Q52589214-C6C85773-7AE2-4916-A79E-8C9D2BE92CE1
P2860
Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Antitumor effect of FGFR inhib ...... an FGFR2-CCDC6 fusion protein.
@en
type
label
Antitumor effect of FGFR inhib ...... an FGFR2-CCDC6 fusion protein.
@en
prefLabel
Antitumor effect of FGFR inhib ...... an FGFR2-CCDC6 fusion protein.
@en
P2093
P2860
P50
P1433
P1476
Antitumor effect of FGFR inhib ...... an FGFR2-CCDC6 fusion protein
@en
P2093
Albert Ndzengue
Benjamin R Kipp
Catherine D Moser
Emily G Barr Fritcher
Hassan M Shaleh
Loretta K Allotey
Melissa S McNulty
Michael P Gustafson
P2860
P304
P356
10.1016/J.CANLET.2016.05.017
P407
P577
2016-05-20T00:00:00Z